FDA Calendar

Company Name Daiichi Sankyo Company Limited
Drug Name Quizartinib (NDA)
Event Name FDA decision on Quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia
Event Date 08/25/2019
Outcome Date
Outcome FDA issues Complete Response Letter for Quizartinib on June 21
Drug Status Priority review
Rival Drugs
Market Potential
Other Approvals
Return to FDA Calendar